Gilead Sciences, facing mounting criticism over the high price of its new hepatitis C pill Sovaldi, has offered to supply the medicine to Egypt at a 99 percent discount to the U.S. price...[The] drug will still cost $900 for a 12-week course of treatment...Gilead said it was "pleased to have finalized an agreement" for the introduction of Sovaldi in Egypt, which has the highest prevalence rate of hepatitis C in the world. "We believe Sovaldi could have a major impact on public health in Egypt..." Gregg Alton, head of corporate and medical affairs at Gilead, said... Egyptian health minister Adel El-Adawi said Cairo had struck a deal with...Gilead for the government to buy Sovaldi for $300 for a one-month box, according to a recent report on the state news agency...Nowhere is the problem more acute than in Egypt, which has the world's highest prevalence of the virus... [also refers to Johnson & Johnson, AbbVie, Bristol-Myers Squibb, Merck]